Objectives Clozapine (CLZ) is prescribed to (relatively) treatment-resistant patients with
schizophrenia spectrum disorders. Currently, it is unknown what factors predict response to …

Clozapine is the only licensed pharmacotherapy for treatment-resistant schizophrenia.
However, response to clozapine is variable. Understanding the demographic and clinical …

Background Clozapine has been serving as the gold standard medication for patients with
treatment-resistant schizophrenia who failed to respond to other antipsychotics. However …

Background Clozapine remains the only evidence-based treatment for treatment-resistant
schizophrenia, and prediction of clozapine response is important in developing stratified …

Background: Clozapine is the recommended antipsychotic for treatment-resistant
schizophrenia (TRS) but there is significant variability between patients in the degree to …

BACKGROUND: Several lines of evidence suggest that clozapine is more effective than both
first-and second-generation antipsychotic drugs in treatment-resistant schizophrenia (TRS) …

Objectives Despite clozapine's superior clinical efficacy in Treatment Resistant
Schizophrenia (TRS), its adverse effects, need for periodic leukocyte monitoring, cost and …

Background: Clozapine is the drug of choice indicated for treatment-resistant schizophrenia
(TRS), but delays in initiation and underutilization might have affected its effectiveness in …

Clozapine is the most effective antipsychotic for the 25% to 33% of people with
schizophrenia who are treatment resistant, but not all people achieve response. Using data …

Background Clozapine has unique efficacy for symptoms in treatment-resistant
schizophrenia; however, symptomatic remission is not necessary nor sufficient for functional …